ea0022p356 | Diabetes | ECE2010
Rizzo Manfredi
, Berneis Kaspar
, Vekic Jelena
, Rini Giovam Battista
, Koulouris Spyridon
, Sakellariou Dimitrios
, Pastromas Socrates
, Manolis Antonis
Background: There is evidence that rosiglitazone may increase cardiovascular risk and, on this basis, this agent has been recently advised for treatment of type-2 diabetes. Yet, its effects on fasting and postprandial atherogenic dyslipidemia are still not fully elucidated.Methods: In an open-label study rosiglitazone (4 mg/day for 12 weeks) was added on top of a maximum of two oral antidiabetic drugs to 18 patients with adequately controlled type-2 diab...